🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Edaravone in the Treatment of Optic Neuritis

RecruitingNAAges 18 Years - 70 YearsAllFirst Affiliated Hospital of Guangxi Medical Univ…
NCT05540262 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis 2. Patients with a first episode of optic neuritis in either eye 3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone Exclusion Criteria: 1. Myopia over 6 diopters 2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity
💊

What it tests

  • Edaravone
📍

Where

1 site
Yi Du
Nanning, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy